UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DCD.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~March~~April 1029, 2008

IMMUNICON CORPORATION

(Exact Name of Registrant Specified in Charter)

Delaware		000-50677		23-2269490
(State or Other Jurisdiction of Incorporation)		(Commission ~~File Number~~FileNumber)		(I.R.S. Employer Identification No.)

3401 Masons Mill Road, Suite 100

Huntingdon Valley, Pennsylvania

19006

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (215) 830-0777

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2 3.0501. ~~Costs~~Notice ~~Associated~~of ~~with~~Delisting ~~Exit~~or Failure to Satisfy a Continued Listing Rule or ~~Disposal~~Standard; ~~Activities.~~Transfer of Listing.

On ~~March~~April 1029, 2008, Immunicon Corporation (~~the~~ “~~Company~~Immunicon”) orissued a press release announcing that on April 29, 2008, its common stock began quotation on the Over-the-Counter Bulletin Board (“~~Immunicon~~OTCBB”). ~~committed~~As todisclosed ~~actions~~previously, toImmunicon ~~reduce~~had ~~staff~~received ~~levels~~notification ~~and~~from ~~incur certain~~The ~~expenses~~NASDAQ inStock ~~order~~Market to(“NASDAQ”) ~~better~~indicating ~~facilitate~~that ~~the~~trading ~~Company~~in Immunicon’s ~~current~~common ~~strategy,~~stock ~~near-term~~would be ~~outlook~~suspended and ~~ongoing~~Immunicon’s ~~operations.~~common ~~This~~stock ~~initiative~~would ~~principally~~be ~~includes~~delisted afrom ~~workforce~~The ~~reduction~~NASDAQ ofCapital ~~approximately~~Market ~~40%~~at the opening of ~~the~~business ~~Company’s~~on ~~full-time~~April 29, ~~equivalent staff~~2008, ~~primarily~~unless inImmunicon ~~platform~~appealed ~~development~~NASDAQ’s ~~programs~~determination. In response, ~~research~~on ~~and~~April 18, ~~development~~2008, ofImmunicon notified ~~new~~NASDAQ ~~products,~~that ~~marketing~~it ofwould ~~current~~not ~~and~~submit ~~new~~such ~~products~~a ~~and~~plan ~~related~~but ~~roles~~rather atwould ~~the~~pursue ~~Company~~quotation ~~(the~~of ~~“Restructuring”)~~its common stock on OTCBB.

~~The~~A ~~Restructuring~~copy ~~reflects, and is a result~~ of ~~the detailed analysis of, several factors, including~~ Immunicon’s ~~revenue~~press ~~outlook~~release ~~and~~announcing ~~current~~quotation ~~expense structure; the adverse March 3, 2008 final decision in the Company’s arbitration with Veridex LLC, a Johnson & Johnson company, and the potential effect~~ of ~~the~~its ~~final~~common ~~decision~~stock on ~~Immunicon’s~~OTCBB ~~commercialization~~is ~~efforts; Immunicon’s~~attached ~~desire~~hereto toas ~~reduce~~Exhibit ~~its~~99.1 ~~cost structure; Immunicon’s desire to preserve stockholder value;~~ and ~~management’s~~is ~~assessment~~incorporated ofherein ~~continued~~by ~~risk and uncertainty regarding the ability at the present time to extrapolate with confidence instrument placement and revenue growth rates~~reference.

~~The~~Item ~~Company anticipates taking a charge in the first fiscal quarter of 2008 of between approximately $1~~9.~~3 and $1~~01.5 ~~million~~Financial ~~for~~Statements ~~severance~~ and ~~other costs related to the Restructuring~~Exhibits.

On March 10, 2008, Immunicon issued a press release announcing the Restructuring. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated into this Item 2.05 by reference.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

James L. Wilcox and Michael Kagan were terminated as part of the Restructuring from their current respective positions at the Company of Vice President and Chief Counsel and Vice President, Manufacturing. Mr. Wilcox’s termination is effective as of March 10, 2008 and Mr. Kagan’s termination is effective as of March 14, 2008. Mr. Wilcox and Mr. Kagan’s terminations are not as a result of any disagreement with Immunicon on any matter relating to the Company’s operations, policies or practices.

Pursuant to the terms of that certain Letter Agreement, dated as of February 4, 2004, between Immunicon and Mr. Wilcox, Mr. Wilcox will receive a severance package consisting of a payment equal to twelve (12) months of his base salary and continuation of certain benefits under Immunicon’s benefit plans for the twelve (12) month period following his termination.

Mr. Kagan will receive a severance package consisting of a payment equal to six (6) months of his base salary and continuation of certain benefits under Immunicon’s benefit plans for the two (2) month period following his termination.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 – Press release.

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~Immunicon~~the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNICON CORPORATION By: ~~/s/~~ BYRON D. HEWETT Byron D. Hewett President and Chief Executive Officer

Dated: ~~March~~April 1029, 2008

EXHIBIT INDEX

Exhibit No.		Document
99.1		Press release.

Filing Compare · IMMUNICON CORP